The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with ...

( MENAFN - EIN Presswire) Spravato® (esketamine) has been approved for use as a standalone treatment for depression, without the requirement of an accompanying antidepressant. Legal Disclaimer: ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

For those with major depression, there is a new treatment option - one that offers hope when patients are not responding to existing treatment. The ...

The U.S. Food and Drug Administration recently expanded approval of the nasal spray SPRAVATO, a ketamine-derived drug, as a treatment for depression. A clinic in Denver is looking to help those ...

Why We Need Fast-Acting Anxiety Relief Now More Than Ever Anxiety isn’t just feeling nervous before a big event—it can be relentless, overwhelming, and even debilitating. Traditional treatments like ...

An estimated 21 million American adults suffer from clinical depression. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few ...